You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Table 1.  

Year Cigarettes Little cigars Large cigars Pipe tobacco Roll-your-own tobacco Moist snuff
Million packs soldb Packs per capitac Million CPEs soldb CPEs per capita Million sticks soldd Sticks per capita Million CPEs solde CPEs per capita Million CPEs solde CPEs per capita Million CPEs soldf CPEs per capita
2000 21,124.76 101.01 112.65 0.54 3,409.69 16.30 169.81 0.81 280.93 1.34 2,049.40 9.80
2001 20,605.07 97.06 108.57 0.51 3,563.75 16.79 152.80 0.72 268.81 1.27 2,129.63 10.03
2002 19,762.18 92.05 112.39 0.52 3,706.29 17.26 143.76 0.67 328.31 1.53 2,205.87 10.27
2003 18,834.13 86.79 114.78 0.53 4,018.50 18.52 129.09 0.59 369.63 1.70 2,298.08 10.59
2004 18,780.37 85.56 135.08 0.62 4,319.16 19.68 121.37 0.55 399.26 1.82 2,435.07 11.09
2005 18,148.6 81.75 188.60 0.85 4,436.11 19.98 120.88 0.54 482.99 2.18 2,522.36 11.36
2006 18,228.49 81.15 209.58 0.93 4,508.08 20.07 107.76 0.48 512.49 2.28 2,581.24 11.49
2007 17,419.64 76.67 238.51 1.05 4,663.03 20.52 97.61 0.43 537.35 2.36 2,741.22 12.06
2008 16,769.2 72.91 273.55 1.19 4,672.74 20.32 98.70 0.43 630.37 2.74 2,800.49 12.18
2009 15,419.39 66.28 107.53 0.46 7,981.90 34.31 333.20 1.43 359.12 1.54 2,919.42 12.55
2010 14,639.62 62.41 44.83 0.19 9,940.95 42.38 691.76 2.95 184.00 0.78 3,086.37 13.16
2011 14,317.63 60.24 37.69 0.16 9,997.56 42.07 1,020.27 4.29 152.22 0.64 3,218.50 13.54
2012 13,991.92 58.25 35.24 0.15 9,438.75 39.30 1,132.15 4.71 131.71 0.55 3,357.06 13.98
2013 13,304.4 54.88 30.53 0.13 7,783.00 32.10 1,212.19 5.00 112.72 0.46 3,482.77 14.37
2014 12,724.33 51.99 27.12 0.11 6,961.14 28.44 1,169.49 4.78 94.53 0.39 3,522.71 14.39
2015 12,986.03 52.57 26.53 0.11 5,757.43 23.31 1,124.42 4.55 107.95 0.44 3,614.78 14.63
2016 12,491.24 50.11 23.77 0.10 5,056.76 20.28 1,077.77 4.32 91.29 0.37 3,716.81 14.91
2017 11,964.83 47.59 20.73 0.08 5,168.61 20.56 1,089.68 4.33 76.51 0.30 3,730.76 14.84
2018 11,345.8 44.78 17.81 0.07 5,018.61 19.81 1,015.58 4.01 60.59 0.24 3,677.15 14.51
2019 10,670.03 41.81 7.75 0.03 4,666.35 18.29 964.12 3.78 56.69 0.22 3,615.30 14.17
2020 10,792.93 42.29 8.70 0.03 4,357.01 17.07 924.51 3.62 53.58 0.21
AAPCg (95% CI) [P value] −3.5 (−3.6 to −3.3) [<.001] −12.1 (−19.0 to −4.6) [<.001] 0.7 (−2.3 to 3.9) [.60] 9.4 (7.8 to 11.0) [<.001] −7.7 (−10.7 to −4.6) [<.001] 3.0 (2.7 to 3.4) [<.001]

Table 1. Total Sales of Various Tobacco Products in Standardized Units of Cigarette Packs or CPEs, 2000–2020, USa

Abbreviations: —, does not apply; AAPC, average annual percentage change; CPE, cigarette pack equivalent.
a Data sources: Data on taxable removals (actual sales) of cigarettes, little cigars, large cigars, pipe tobacco, and RYO tobacco were obtained from the Alcohol and Tobacco Tax and Trade Bureau, US Department of the Treasury (17). Data on volume sales of smokeless tobacco were obtained from the US Federal Trade Commission for 2000–2019 (18).
b The number of cigarette packs and CPEs for little cigars was calculated by dividing the number of sticks by 20. Little cigars resemble cigarettes in all respects and so were considered direct equivalents.

c Adult per capita sales based on the US adult population aged ≥18 years using data from the US Census Bureau for each year.
d Large cigars were not converted to CPEs because of variations in size and tobacco content.
e CPEs for pipe and RYO loose smoking tobacco were based on weight (14.6 g tobacco per cigarette pack).
f Moist snuff CPEs assumed the equivalence of a 1.2 oz tin to 2.5 packs of cigarettes based on consumption.
g Overall linear trend during 2000–2020; significant difference defined as P < .05.

Table 2.  

Characteristic Cigarettes Cigars Roll-your-own tobacco Pipe Smokeless tobaccob
2002 2019 2002 2019 2002 2019 2002 2019 2002 2019
Overall 27.4 (26.7–28.1) 18.2 (17.7–18.7)c 5.4 (5.1–5.8) 4.6 (4.3–4.8)c 2.6 (2.4–2.9) 3.0 (2.8–3.3)c 0.8 (0.6–1.0) 0.7 (0.6–0.9) 3.5 (3.2–3.7) 3.3 (3.1–3.5)c
Sex
Female 24.5 (23.6–25.5) 16.3 (15.7–17.0)c 1.6 (1.4–1.8) 2.0 (1.8–2.3)c 1.8 (1.5–2.1) 2.4 (2.1–2.7)c 0.3 (0.1–0.4) 0.3 (0.2–0.4) 0.5 (0.3–0.6) 0.6 (0.5–0.7)
Male 30.8 (29.7–31.9) 20.3 (19.5–21.1)c 9.6 (9.0–10.3) 7.3 (6.8–7.8)c 3.5 (3.1–3.9) 3.7 (3.4–4.1)c 1.4 (1.1–1.7) 1.2 (1.0–1.4) 6.7 (6.2–7.3) 6.2 (5.8–6.6)c
Age, y
18–25 40.8 (39.9–41.7) 17.8 (17.0–18.6)c 11.0 (10.4–11.6) 7.7 (7.1–8.2)c 4.5 (4.2–4.9) 3.2 (2.8–3.5)c 1.1 (0.9–1.3) 1.3 (1.1–1.5)c 4.9 (4.5–5.3) 5.0 (4.5–5.4)c
26–34 32.7 (31.1–34.3) 23.6 (22.5–24.8)c 6.6 (5.8–7.5) 6.4 (5.8–7.1) 3.4 (2.8–4.1) 3.6 (3.1–4.1)c 0.5 (0.3–0.7) 1.0 (0.7–1.3)c 5.4 (4.7–6.1) 4.4 (3.8–4.9)
35–49 30.8 (29.6–32.0) 21.6 (20.7–22.6)c 5.8 (5.2–6.5) 4.5 (4.1–5.0)c 3.2 (2.7–3.7) 3.3 (2.9–3.6)c 0.5 (0.3–0.7) 0.6 (0.4–0.7) 3.2 (2.8–3.7) 4.1 (3.7–4.6)c
≥50 17.3 (16.0–18.7) 14.7 (13.8–15.5)c 2.4 (1.9–2.9) 3.0 (2.6–3.5) 1.0 (0.7–1.4) 2.7 (2.3–3.0)c 1.0 (0.6–1.4) 0.6 (0.4–0.8)c 2.3 (1.8–2.8) 2.0 (1.7–2.4)
Race and ethnicity
African American 28.2 (26.0–30.4) 20.8 (19.3–22.3)c 7.1 (6.0–8.2) 8.7 (7.7–9.6)c 4.5 (3.5–5.4) 3.4 (2.8–4.0) 0.4 (0.1–0.7) 0.7 (0.4–0.9) 1.7 (1.1–2.4) 1.3 (0.9–1.8)c
Hispanic 25.0 (22.8–27.2) 13.5 (12.4–14.7)c 5.2 (4.2–6.3) 3.3 (2.8–3.9)c 3.9 (3.0–4.9) 2.2 (1.7–2.6)c 0.3 (0.1–0.4) 0.5 (0.3–0.7)c 0.5 (0.3–0.8) 0.9 (0.7–1.1)c
Otherd 25.5 (22.1–28.9) 14.5 (12.9–16.1)c 2.7 (2.0–3.4) 2.9 (2.3–3.6) 4.2 (2.9–5.5) 2.8 (2.1–3.5)c e 1.0 (0.6–1.4) 1.8 (1.1–2.4) 2.3 (1.6–2.9)
White 28.0 (27.2–28.8) 19.5 (18.8–20.1)c 5.4 (5.0–5.8) 4.3 (4.0–4.7)c 2.0 (1.8–2.2) 3.2 (2.9–3.5)c 1.0 (0.7–1.2) 0.8 (0.6–0.9) 4.4 (4.0–4.7) 4.5 (4.2–4.8)c
Annual household income, $
≤19,999 35.5 (33.8–37.3) 30.1 (28.5–31.6)c 5.7 (5.1–6.4) 6.5 (5.8–7.3)c 5.4 (4.7–6.2) 7.7 (6.8–8.6)c 0.9 (0.7–1.2) 1.5 (1.1–1.9)c 3.1 (2.5–3.7) 3.3 (2.7–3.8)
20,000–49,999 29.7 (28.5–30.8) 21.7 (20.7–22.7)c 5.0 (4.5–5.5) 4.4 (3.9–4.9) 2.8 (2.4–3.3) 3.6 (3.2–4.1)c 0.8 (0.5–1.0) 0.8 (0.6–1.0) 3.7 (3.3–4.2) 3.1 (2.7–3.5)
50,000–74,999 24.6 (23.0–26.3) 17.8 (16.5–19.0)c 4.9 (4.1–5.7) 4.2 (3.6–4.8)c 1.4 (1.1–1.8) 2.3 (1.8–2.9)c 0.8 (0.2–1.4) 0.7 (0.4–0.9) 3.6 (2.9–4.3) 3.4 (2.8–3.9)c
≥75,000 19.7 (18.3–21.1) 11.7 (11.1–12.4)c 6.3 (5.5–7.1) 4.1 (3.7–4.6)c 0.8 (0.6–1.1) 1.2 (1.0–1.4)c 0.7 (0.4–1.0) 0.5 (0.3–0.6) 3.2 (2.7–3.8) 3.5 (3.1–3.8)c
Education
Less than high school diploma 35.2 (33.3–37.0) 26.7 (25.0–28.4)c 5.9 (5.1–6.8) 5.2 (4.4–6.0) 5.2 (4.4–6.0) 6.6 (5.7–7.5)c 0.8 (0.5–1.0) 1.0 (0.7–1.3) 4.1 (3.3–4.9) 3.3 (2.7–3.9)
High school diploma 32.3 (31.0–33.6) 25.2 (24.0–26.3)c 5.4 (4.8–5.9) 5.3 (4.7–5.9)c 3.0 (2.6–3.4) 4.7 (4.2–5.3)c 0.8 (0.5–1.1) 1.1 (0.8–1.3)c 4.2 (3.7–4.7) 4.5 (4.0–5.0)c
Some college 29.0 (27.6–30.5) 20.3 (19.4–21.2)c 6.0 (5.3–6.7) 5.0 (4.5–5.5)c 2.1 (1.6–2.5) 2.7 (2.3–3.0)c 1.0 (0.6–1.5) 0.8 (0.6–1.0) 3.3 (2.8–3.8) 3.9 (3.5–4.3)c
College degree or more 14.5 (13.4–15.7) 8.1 (7.5–8.8)c 4.6 (4.0–5.3) 3.4 (3.0–3.9)c 0.9 (0.6–1.1) 0.8 (0.6–1.0) 0.6 (0.3–0.9) 0.4 (0.2–0.5) 2.3 (1.9–2.8) 1.9 (1.6–2.2)

Table 2. Prevalence of Self-Reported Current (Past 30-Day) Use of Cigarettes and Noncigarette Tobacco Products Among US Adults Aged ≥18 Years, by Demographic Characteristics, National Survey on Drug Use and Health, 2002–2019a

a Data source: Substance Abuse and Mental Health Services Administration (16). All values are percentage (95% CI).
b Prevalence of smokeless tobacco use showed an increasing trend in the adjusted analysis.
c Significant linear trend during 2002–2019 (P < .05). Linear trend assessed in a binary logistic regression model using orthogonal polynomials that adjusted for age, sex, and race and ethnicity.

d Includes American Indian/Alaska Native, Pacific Islander.
e Estimate not presented because relative standard error was ≥40%.

Table 3.  

Characteristic Cigarettes Cigars Pipe Smokeless tobacco
2002 2019 2002 2019 2002 2019 2002 2019
Overall 73.4 (72.6–74.2) 59.5 (58.8–60.2)b 40.0 (39.1–40.8) 33.8 (33.2–34.5)b 18.6 (17.8–19.3) 12.5 (12.0–13.0)b 21.2 (20.5–21.9) 16.6 (16.1–17.1)b
Sex
Female 68.5 (67.3–69.6) 54.8 (53.9–55.8)b 19.3 (18.5–20.2) 18.3 (17.6–19.0)b 4.5 (3.9–5.0) 3.8 (3.4–4.2) 6.7 (6.1–7.3) 5.2 (4.9–5.6)b
Male 78.7 (77.7–79.7) 64.5 (63.6–65.5)b 62.3 (61.1–63.5) 50.5 (49.4–51.5)b 33.8 (32.6–35.1) 21.7 (20.9–22.6)b 36.9 (35.7–38.0) 28.8 (27.9–29.7)b
Age, y
18–25 71.3 (70.5–72.1) 43.4 (42.3–44.4)b 45.8 (44.9–46.7) 30.8 (29.8–31.8)b 8.1 (7.6–8.6) 7.9 (7.3–8.4)b 23.9 (23.2–24.7) 16.6 (15.8–17.4)b
26–34 73.0 (71.4–74.6) 60.0 (58.7–61.4)b 41.5 (39.8–43.2) 40.1 (38.8–41.5) 9.5 (8.6–10.5) 10.6 (9.7–11.4)b 29.1 (27.6–30.6) 20.8 (19.7–21.9)b
35–49 75.8 (74.6–77.0) 62.5 (61.3–63.6)b 42.2 (40.9–43.6) 37.1 (36.0–38.3)b 16.7 (15.7–17.7) 8.6 (8.0–9.3)b 21.4 (20.3–22.5) 20.0 (19.1–21.0)b
≥50 72.4 (70.8–74.0) 62.5 (61.3–63.7)b 35.1 (33.4–36.8) 30.8 (29.6–31.9)b 28.2 (26.6–29.9) 16.5 (15.6–17.5)b 16.4 (15.1–17.7) 13.3 (12.4–14.1)b
Race/ethnicity
African American 63.7 (61.3–66.1) 45.2 (43.3–47.1)b 29.8 (27.4–32.2) 24.5 (22.9–26.1)b 12.3 (10.3–14.3) 5.5 (4.6–6.3)b 13.5 (11.6–15.3) 6.9 (5.9–7.8)b
Hispanic 61.1 (58.5–63.7) 46.4 (44.6–48.1)b 27.6 (25.4–29.8) 23.1 (21.6–24.5)b 6.8 (5.3–8.3) 5.2 (4.4–6.0)b 9.0 (7.7–10.4) 8.6 (7.7–9.6)
Other 59.6 (55.4–63.7) 41.8 (39.4–44.2)b 26.9 (23.5–30.3) 22.4 (20.4–24.3)b 9.9 (7.6–12.3) 7.2 (6.0–8.4)b 13.6 (11.2–15.9) 9.7 (8.5–10.9)b
White 78.1 (77.2–78.9) 68.1 (67.3–68.9)b 44.7 (43.7–45.7) 40.0 (39.1–40.8)b 22.2 (21.3–23.1) 16.4 (15.7–17.1)b 25.1 (24.2–25.9) 21.4 (20.7–22.1)b
Annual household income, $
≤19,999 67.9 (66.1–69.7) 57.1 (55.4–58.8)b 30.7 (29.1–32.4) 25.5 (24.0–27.0)b 12.9 (11.6–14.2) 11.1 (10.0–12.2)b 18.3 (16.8–19.7) 13.7 (12.6–14.9)b
20,000–49,999 73.0 (71.8–74.3) 58.9 (57.7–60.2)b 37.6 (36.3–38.9) 29.0 (27.8–30.2)b 18.1 (17.0–19.2) 11.8 (10.9–12.7)b 20.8 (19.8–21.8) 13.7 (12.8–14.5)b
50,000–74,999 75.7 (73.9–77.5) 61.2 (59.6–62.9)b 43.0 (41.0–45.0) 34.5 (32.8–36.1)b 19.2 (17.4–20.9) 12.9 (11.7–14.0)b 22.5 (21.0–24.1) 16.6 (15.4–17.8)b
≥75,000 76.7 (75.2–78.2) 60.1 (59.0–61.2)b 49.1 (47.3–50.9) 40.0 (38.8–41.1)b 23.5 (21.9–25.2) 13.3 (12.4–14.1)b 23.3 (21.8–24.7) 19.7 (18.8–20.5)
Education
Less than high school diploma 67.1 (65.1–69.1) 54.9 (52.8–56.9)b 30.6 (28.7–32.4) 22.3 (20.6–24.0)b 14.7 (13.2–16.2) 8.5 (7.4–9.6)b 20.5 (18.8–22.3) 12.6 (11.4–13.9)b
High school diploma 74.7 (73.3–76.0) 61.5 (60.1–62.8)b 37.2 (35.8–38.5) 30.0 (28.7–31.3)b 16.6 (15.4–17.8) 11.0 (10.1–11.9)b 21.6 (20.5–22.8) 17.4 (16.4–18.4)b
Some college 76.7 (75.3–78.1) 62.4 (61.2–63.6)b 43.1 (41.4–44.7) 36.0 (34.8–37.1)b 18.9 (17.5–20.4) 13.8 (12.9–14.7)b 22.0 (20.8–23.3) 18.6 (17.7–19.5)
College degree or more 72.8 (71.2–74.4) 57.1 (55.8–58.4)b 47.1 (45.4–48.9) 38.8 (37.6–40.1)b 23.5 (21.9–25.0) 13.8 (12.8–14.7)b 20.3 (19.0–21.6) 15.5 (14.6–16.4)b

Table 3. Prevalence of Self-Reported Ever Use of Cigarettes and Noncigarette Tobacco Products Among US Adults Aged ≥18 Years, National Survey on Drug Use and Health, 2002–2019a

a Data source: Substance Abuse and Mental Health Services Administration (16). All values are percentage (95% CI).
b Significant linear trend during 2002–2019 (P < .05). Linear trend assessed in a binary logistic regression model using orthogonal polynomials that adjusted for age, sex, and race and ethnicity.

CME / ABIM MOC

20-Year Trends in Tobacco Sales and Self-Reported Tobacco Use in the United States, 2000–2020

  • Authors: Lungile Nkosi, PhD, MPH; Satomi Odani, MPH; Israel T. Agaku, PhD
  • CME / ABIM MOC Released: 7/28/2022
  • Valid for credit through: 7/28/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for public health/prevention officials, family practitioners, internists, and other clinicians acting as advocates against tobacco use or who treat and manage patients using tobacco.

The goal of this activity is for learners to be better able to describe 20-year trends in tobacco use in the United States from 2000 to 2020, based on sales data for cigarettes, cigars, roll-your-own tobacco, and pipes from the US Department of the Treasury, standardized to cigarette packs and cigarette pack equivalents, as well as self-reported data on past 30-day tobacco use for those aged 18 years and older from The National Survey on Drug Use and Health.

Upon completion of this activity, participants will:

  • Evaluate 20-year trends in US tobacco use from 2000 to 2020, overall and for cigarettes and cigars, based on sales and self-reported data
  • Assess 20-year trends in US pipe and roll-your-own tobacco use from 2000 to 2020, based on sales and self-reported data
  • Describe public health implications of 20-year trends in US tobacco use from 2000 to 2020, based on sales and self-reported data


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Lungile Nkosi, PhD, MPH

    Sefako Makgatho Health Sciences University, Africa Centre for Tobacco Industry Monitoring and Policy Research, South Africa

  • Satomi Odani, MPH

    Osaka International Cancer Institute, Cancer Control Center, Osaka, Japan

  • Israel T. Agaku, PhD

    Harvard School of Dental Medicine, Dental School, Boston, MA, United States

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer
    Medscape, LLC

    Disclosures

    Laurie Barclay, MD, has the following relevant financial relationships:
    Formerly owned stocks in: AbbVie

Editor

  • Ellen Taratus, MS

    Senior Editor
    Preventing Chronic Disease 
    Atlanta, GA

Compliance Reviewer

  • Leigh A. Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance
    Medscape, LLC

    Disclosures

    Leigh A. Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Preventing Chronic Disease. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

20-Year Trends in Tobacco Sales and Self-Reported Tobacco Use in the United States, 2000–2020

Authors: Lungile Nkosi, PhD, MPH; Satomi Odani, MPH; Israel T. Agaku, PhDFaculty and Disclosures

CME / ABIM MOC Released: 7/28/2022

Valid for credit through: 7/28/2023

processing....

Abstract and Introduction

Abstract

Introduction

In the past 2 decades, many tobacco control policies were enacted, and several new or modified products were introduced into the US marketplace. Continued tobacco surveillance is critical in this evolving landscape. We examined 20-year trends in tobacco use from sales and self-reported data.

Methods

We obtained data on taxable removals (sales) of cigarettes, cigars, roll-your-own (RYO) tobacco, and pipe tobacco from the US Department of the Treasury. We assessed self-reported past 30-day tobacco use from the National Survey on Drug Use and Health among people aged 18 years or older. Volume sales were standardized to cigarette packs and cigarette pack equivalents (CPEs) and trends measured by using joinpoint and logistic regression.

Results

From 2000 to 2019–2020, declines occurred in per capita sales of cigarettes (101.01 to 42.29 packs/capita), little cigars (0.54 to 0.03 CPEs/capita), and RYO tobacco (1.34 to 0.21 CPEs/capita). Volume sales also decreased for chewing tobacco and scotch/dry snuff (all P < .05). Conversely, volume sales increased for pipe tobacco, moist snuff, and snus for the respective assessed periods. Large cigar volume sales did not change significantly. We found consistent trends in self-reported use, except for RYO tobacco (decreased volume sales but increased self-reported use) and pipe smoking (increased volume sales, but trivial self-reported use <1% throughout the study period). Current use of any tobacco product decreased from 32.2% to 22.9% during the assessed period.

Conclusion

Harmonizing the tax and regulatory structure within and across the diversity of tobacco products may help reduce aggregate tobacco consumption in the US.

Introduction

Healthy People sets science-based, 10-year national objectives for improving the nation’s health and well-being [1,2]. Tobacco-related Healthy People 2030 objectives include reducing adult tobacco use to 16.2% or less (from 20.1% in 2018), current cigarette smoking to 5% or less (from 13.9% in 2019), and any combustible tobacco use (ie, cigarettes, cigars, pipes) to 5% or less (from 16.8% in 2018) [2]. Holistically examining long-term trends in the diversity of tobacco products in the US marketplace is important because these products are not independent of one another nor are their trends. Switching from one product to another is largely driven by market forces (eg, product design and marketing) and economic factors (eg, tax imbalances) [3–7]. Yet tobacco products that are close substitutes are being regulated differently [8]. Little cigars and large cigars are both cigars but are taxed differently, as are pipe and roll-your-own (RYO) tobacco, which are both loose forms of smoking tobacco [5,6]. Furthermore, only in August 2016 did the “deeming rule” extend the regulatory authority of the US Food and Drug Administration beyond cigarettes to other similarly harmful combustible products, such as cigars, hookah, and pipe tobacco [9]. Yet these newly deemed combustibles are marketed in a plethora of flavors, whereas cigarette flavors are banned (except menthol) [3,10,11].

It is therefore imperative for policy makers to understand the long-term trends in tobacco product consumption and how these trends may have shifted in response to policy interventions [4,6]. Such information can help eliminate loopholes that dampen the impact of tobacco control policies through tax avoidance strategies [4–6,12]. Some studies have examined trends in US tobacco consumption over varying lengths of time by using both population and sales data [13–15]; however, no recent study has examined trends over the past 2 decades to gain insights into longer-term trends that may be different from year-on-year changes, seasonal variations, or even multiyear trends over shorter periods of time. To fill this gap, we examined changes in the consumption of cigarettes, cigars, smokeless tobacco, RYO tobacco, and pipe tobacco during the 20-year period from 2000 to 2020. Analyzed data comprised both volume sales data (2000–2020) and self-reported data (2002–2019).